IP Library Granted Patent US 11,642,406
Granted Patent B2
US 11,642,406 · App. 16/717,509 · Granted May 9, 2023

Compositions comprising

Inventors: Chitrananda Abeygunawardana (Ambler, PA); Yadong Adam Cui (Norristown, PA); Romulo Ferrero (Westfield, NJ); Jian He (Blue Bell, PA); Luwy Musey (Blue Bell, PA); Tanaz Petigara (Philadelphia, PA); Julie M. Skinner (Phoenixville, PA)
Assignee: Merck Sharp & Dohme LLC
A61K39/092A61K47/20A61K47/61A61K47/62A61P31/04A61P37/04A61K2039/55588A61K2039/6037A61K2039/6068A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,642,406
App. No.
16/717,509
Granted
May 9, 2023
Kind
B2
Abstract

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae . The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Claims (9)

1. A multivalent immunogenic composition comprising 24 distinct S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes are 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-acetylated 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM197, and wherein the composition does not comprise polysaccharide carrier protein conjugates containing polysaccharides of any other S. pneumoniae serotype.

2. The multivalent immunogenic composition of claim 1 , wherein the composition comprises an adjuvant.

3. The multivalent immunogenic composition of claim 2 wherein the adjuvant is an aluminum phosphate adjuvant.

4. A multivalent immunogenic composition comprising S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-acetylated 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM197.

5. The multivalent immunogenic composition of claim 4 , wherein the composition comprises an adjuvant.

6. The multivalent immunogenic composition of claim 5 wherein the adjuvant is an aluminum phosphate adjuvant.

7. A multivalent immunogenic composition comprising S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist essentially of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-acetylated 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM197.

8. The multivalent immunogenic composition of claim 7 , wherein the composition comprises an adjuvant.

9. The multivalent immunogenic composition of claim 8 wherein the adjuvant is an aluminum phosphate adjuvant.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2019
From: ABEYGUNAWARDANA, CHITRANANDA; CUI, YADONG ADAM; FERRERO, ROMULO; HE, JIAN; MUSEY, LUWY; PETIGARA, TANAZ; SKINNER, JULIE M.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 051309/0793 →
Continuity (3)
Provisional Application 62853331 · May 28, 2019
Provisional Application 62781835 · Dec 19, 2018
Related Publication 20200197503A1 · Jun 25, 2020